Quest Diagnostics (DGX) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Go back to Quest Diagnostics (DGX) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

April 21, 2026 6:47 AM EDT

First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83

SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:... More